Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood. Patients with heart attacks are treated with medicines to reduce the clotting action of platelets. This study is trying to determine whether erythropoietin alters the clotting action of platelets in patients receiving anti-platelet medicines. It is important to understand the effects of erythropoietin on platelets since preliminary studies in animals suggest that erythropoietin may protect the heart from damage during a heart attack.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: American Heart Association
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Age 21-75 years

• Clinical evidence of acute myocardial infarction (MI) with total or sub-total occlusion on angiogram

• Status post percutaneous revascularization procedure for acute MI with TIMI 3 flow

• Ongoing clinically-indicated treatment with aspirin, thienopyridines

Exclusion Criteria:

• Hemodynamic instability/shock or severe congestive heart failure

• Time from onset of chest pain to revascularization procedure > 16 hours

• Use of intravenous thrombolytic agents for treatment of MI

• Known need for additional revascularization procedures